These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34841028)

  • 1. Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis.
    Goldberg RH; Matthews NH; Hristov AC; Wang F
    JAAD Case Rep; 2021 Dec; 18():71-73. PubMed ID: 34841028
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
    Stekolchik E; Saul D; Chidekel A
    Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
    Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
    Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.
    Korten I; Kieninger E; Krueger L; Bullo M; Flück CE; Latzin P; Casaulta C; Boettcher C
    Front Pediatr; 2022; 10():852551. PubMed ID: 35529332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
    Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
    JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
    Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
    J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.
    Lee T; Sawicki GS; Altenburg J; Millar SJ; Geiger JM; Jennings MT; Lou Y; McGarry LJ; Van Brunt K; Linnemann RW
    J Cyst Fibros; 2023 May; 22(3):402-406. PubMed ID: 36581485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
    Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
    J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
    Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
    J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
    Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
    Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
    Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.
    Cheng A; Baker O; Hill U
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.
    Ryan KJ; Guimbellot JS; Dowell AE; Reed-Walker KD; Kerstner-Wood CD; Anderson JD; Liu Z; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123518. PubMed ID: 36371965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
    Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method.
    Reyes-Ortega F; Qiu F; Schneider-Futschik EK
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):987-996. PubMed ID: 33073196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.